Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Allan Saul

Showing results (101-110 of 122) with videos related to

Pageof 13
Sort By:
Vaccine|November 8, 2003
Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean childrenBlaise Genton, Fadwa Al-Yaman, Inoni Betuela, et al.
Lancet (London, England)|September 21, 2002
Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparumDavid J Pombo, Gregor Lawrence, Chakrit Hirunpetcharat, et al.
Vaccine|April 7, 2005
A human phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide ISA720 adjuvantAllan Saul, Greg Lawrence, Anthony Allworth, et al.
The Journal of Infectious Diseases|March 29, 2002
A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New GuineaBlaise Genton, Inoni Betuela, Ingrid Felger, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 18, 2006
Sustained high-titer antibody responses induced by conjugating a malarial vaccine candidate to outer-membrane protein complexYimin Wu, Craig Przysiecki, Elizabeth Flanagan, et al.
The Lancet. Infectious Diseases|December 3, 2013
Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trialsZulfiqar A Bhutta, Maria Rosario Capeding, Ashish Bavdekar, et al.
The American Journal of Tropical Medicine and Hygiene|August 28, 2004
Update on the clinical development of candidate malaria vaccinesW Ripley Ballou, Myriam Arevalo-Herrera, Daniel Carucci, et al.
Ebiomedicine|July 25, 2017
Safety Profile and Immunologic Responses of a Novel Vaccine Against Shigella sonnei Administered Intramuscularly, Intradermally and Intranasally: Results From Two Parallel Randomized Phase 1 Clinical Studies in Healthy Adult Volunteers in EuropeOdile Launay, David J M Lewis, Alessandra Anemona, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 6, 2013
Development of a glycoconjugate vaccine to prevent meningitis in Africa caused by meningococcal serogroup XFrancesca Micoli, Maria Rosaria Romano, Marta Tontini, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 9, 2020
Short Vi-polysaccharide abrogates T-independent immune response and hyporesponsiveness elicited by long Vi-CRM<sub>197</sub> conjugate vaccineFrancesca Micoli, Stefania P Bjarnarson, Melissa Arcuri, et al.
Pageof 13

Showing results (101-110 of 122) with videos related to

Sort By:
Pageof 13
Vaccine|November 8, 2003
Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean childrenBlaise Genton, Fadwa Al-Yaman, Inoni Betuela, et al.
Lancet (London, England)|September 21, 2002
Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparumDavid J Pombo, Gregor Lawrence, Chakrit Hirunpetcharat, et al.
Vaccine|April 7, 2005
A human phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide ISA720 adjuvantAllan Saul, Greg Lawrence, Anthony Allworth, et al.
The Journal of Infectious Diseases|March 29, 2002
A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New GuineaBlaise Genton, Inoni Betuela, Ingrid Felger, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 18, 2006
Sustained high-titer antibody responses induced by conjugating a malarial vaccine candidate to outer-membrane protein complexYimin Wu, Craig Przysiecki, Elizabeth Flanagan, et al.
The Lancet. Infectious Diseases|December 3, 2013
Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trialsZulfiqar A Bhutta, Maria Rosario Capeding, Ashish Bavdekar, et al.
The American Journal of Tropical Medicine and Hygiene|August 28, 2004
Update on the clinical development of candidate malaria vaccinesW Ripley Ballou, Myriam Arevalo-Herrera, Daniel Carucci, et al.
Ebiomedicine|July 25, 2017
Safety Profile and Immunologic Responses of a Novel Vaccine Against Shigella sonnei Administered Intramuscularly, Intradermally and Intranasally: Results From Two Parallel Randomized Phase 1 Clinical Studies in Healthy Adult Volunteers in EuropeOdile Launay, David J M Lewis, Alessandra Anemona, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 6, 2013
Development of a glycoconjugate vaccine to prevent meningitis in Africa caused by meningococcal serogroup XFrancesca Micoli, Maria Rosaria Romano, Marta Tontini, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 9, 2020
Short Vi-polysaccharide abrogates T-independent immune response and hyporesponsiveness elicited by long Vi-CRM<sub>197</sub> conjugate vaccineFrancesca Micoli, Stefania P Bjarnarson, Melissa Arcuri, et al.
Pageof 13